#USA #Paris #Liver Disease #MASLD #Essentiale

New Study Unveils Role of Essential Phospholipids in Managing Fatty Liver Disease

A landmark study has emerged from the EXCEL clinical trial, showcasing the crucial benefits of essential phospholipids, marketed as Essentiale, in the management of Metabolic dysfunction–Associated Steatotic Liver Disease (MASLD), commonly referred to as Fatty Liver Disease. The findings of this first-of-its-kind research indicate that patients treated with essential phospholipids experienced a 2.5 times greater reduction in liver fat compared to those who relied solely on lifestyle modifications such as diet and exercise.

Conducted as a multi-centre, randomized, double-blind, placebo-controlled trial, the EXCEL study specifically targeted individuals grappling with MASLD who also had comorbid conditions like type 2 diabetes, hyperlipidaemia, or obesity. This setup was instrumental in exploring how essential phospholipids can alter treatment outcomes in a population where Fatty Liver Disease is rapidly becoming the most prevalent chronic liver condition globally, expected to affect over 55% of adults by 2040.

Fatty liver disease is often labeled a 'silent' affliction due to its subtle beginnings, but its progression can lead to debilitating symptoms, including abdominal discomfort, fatigue, sleep disturbances, bloating, anxiety, and heightened metabolic risks. Professor Norbert Stefan, a noted expert from the University of Tübingen, highlighted that this research sheds light on the pressing need for early intervention, aligning scientific findings with real patient experiences.

According to Stefan, "This groundbreaking research marks an important moment for the millions of people currently living with MASLD. By demonstrating measurable improvements in liver fat reduction and alleviating fatigue, we reinforce the vital message that effective, evidence-based options can exist to transform outcomes and restore hope for a more energized life in individuals with MASLD."

The EXCEL trial harnessed advanced, non-invasive imaging technologies to quantify liver fat levels, while also utilizing validated questionnaires specifically designed to measure patient wellbeing, known as CLDQ-MASLD scores. The main trial deliverables reveal that introducing essential phospholipids in conjunction with dietary changes and physical activity leads to:

• - 2.5 times greater reduction in liver fat, as determined through FibroScan CAP (Controlled Attenuation Parameter).
• - A statistically significant uptick in patient-reported fatigue, which is a primary yet frequently overlooked symptom of MASLD.
• - Noteworthy reductions in HbA1c levels, a vital indicator of glycemic control in type 2 diabetes patients, further underlining the relevance of these findings for MASLD patients facing metabolic challenges.

Nikunj Thakker, Global Brand General Manager for Essentiale at Opella, remarked that the timing of intervention is crucial: "When caught early, a significant portion of MASLD cases can be reversible. This evidence-backed treatment strategy, deploying essential phospholipids alongside dietary and exercise protocols, not only reduces liver fat but also tackles the debilitating fatigue affecting a large demographic grappling with Fatty Liver Disease."

The comprehensive methodology and results of this pivotal study were formally published in Liver International, spotlighting essential phospholipids as a promising treatment avenue in the fight against Fatty Liver Disease, validating that proactive management can lead to substantial health improvements.

This significant advancement opens a new chapter in the treatment landscape for MASLD patients, emphasizing that positive outcomes are attainable, and highlighting the potential for restoring a more vibrant life for those affected.

For in-depth insights and detailed findings, the full study can be accessed here.